The Medical Letter on Drugs and Therapeutics
Concentrated Insulin Glargine (Toujeo) for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Toujeo (Sanofi), a more concentrated form of insulin glargine containing 300 IU/mL compared to the 100 IU/mL in Lantus (Sanofi). Lantus is nearing the end of its patent protection in the US, and biosimilars are expected to become available.

INSULIN GLARGINE — A long-acting analog of human insulin synthesized by recombinant DNA technology, insulin glargine forms microprecipitates in subcutaneous tissue that prolong its duration of action, permitting once-daily injection in most patients. Toujeo has a more gradual and prolonged release of insulin from the subcutaneous depot than Lantus, resulting in more even activity throughout the dosing period and a longer duration of action. The prolonged time in subcutaneous tissue may reduce the bioavailability of Toujeo.1,2

CLINICAL ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Concentrated Insulin Glargine (Toujeo) for Diabetes
Article code: 1468b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian